One of two of Opthea's phase III trials for a common eye disease has failed to meet its primary endpoints, ... Read More The ...

Theresa Shank Grentz, who played with the Mighty Macs of Immaculata University in the 1970s, recalls her college career on ...

Omeros Corporation today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH).

This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...

At 92 and blind, Babbie Lovett remains committed to fashion, guided by her sense of touch -- and by what seems like an almost ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative ...

The FDA has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the Phase III CATT1 trial for T1D.

Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate ...

The Democrats can never win on the basis of sound, reasoned arguments, so they have to find other ways to try to build the ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing ILU ...